Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus TETRACHEL.
DECLOMYCIN vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic